keyword
https://read.qxmd.com/read/38392779/management-of-polypharmacy-and-potential-drug-drug-interactions-in-patients-with-pulmonary-aspergillosis-a-2-year-study-of-a-multidisciplinary-outpatient-clinic
#21
JOURNAL ARTICLE
Dario Cattaneo, Alessandro Torre, Marco Schiuma, Aurora Civati, Giacomo Casalini, Andrea Gori, Spinello Antinori, Cristina Gervasoni
Pulmonary aspergillosis mainly affects elderly patients, patients with pulmonary complications, patients with hematological malignancies, organ transplant recipients, or critically ill patients. Co-morbidities may result in a high rate of polypharmacy and a high risk of potential drug-drug interaction (pDDI)-related antifungal azoles, which are perpetrators of several pharmacokinetic- and pharmacodynamic-driven pDDIs. Here, we report the results of the first 2-year study of an outpatient clinic focusing on the management of therapies in patients with pulmonary aspergillosis...
January 26, 2024: Journal of Fungi (Basel, Switzerland)
https://read.qxmd.com/read/38391408/risk-factors-and-environmental-preventive-actions-for-aspergillosis-in-patients-with-hematological-malignancies
#22
REVIEW
Daniel Raposo Puglia, José Ángel Raposo Puglia, Emilio García-Cabrera, Fátima Morales, Juan Carlos Camacho-Vega, Ángel Vilches-Arenas
(1) Background: Aspergillus spp. is a widely distributed filamentous fungus in the environment due to its high sporulation capacity. Currently, invasive aspergillosis (IA) is the most common invasive fungal infection in patients with hematologic malignancies, with high rates of mortality and morbidity. The multifactorial nature of the disease requires appropriate risk stratification to enable the most appropriate preventive measures to be adapted and implemented according to the characteristics of the patient...
February 5, 2024: Clinics and Practice
https://read.qxmd.com/read/38387930/-risk-factors-of-late-onset-hemorrhagic-cystitis-after-allogeneic-hematopoietic-stem-cell-transplantation
#23
JOURNAL ARTICLE
Lin-Yi Zhang, Yi-Ying Xiong, Ming-Yan Liao, Qing Xiao, Xiao-Qiong Tang, Xiao-Hua Luo, Hong-Bin Zhang, Li Wang, Lin Liu
UNLABELLED: To analyze the risk factors for late-onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), the risk factors for the progression of LOHC to severe LOHC, and the effect of LOHC on survival. METHODS: The clinical data of 300 patients who underwent allo-HSCT at the First Affiliated Hospital of Chongqing Medical University from January 2015 to December 2021 were retrospectively analyzed. The relevant clinical parameters that may affect the occurance of LOHC after allo-HSCT were selected for univariate and multivariate analysis...
February 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38374006/osteomyelitis-by-microsporum-canis-and-staphylococcus-spp-in-cat-felis-catus-case-report
#24
JOURNAL ARTICLE
Fernanda O Soares, Isabel R Rosado, Marcus V C Sousa, Carolyne F Dumont, Joely F F Bittar, Ian Martin, Marcelo E Beletti, Roberta T Melo, Endrigo G L Alves
BACKGROUND: Staphylococcus spp and Microsporum canis are zoonotic microorganisms which can cause infections and systemic diseases. The bone infection is usually caused by invasion of pathogen through the hematologic route. Mixed osteomyelitis caused by bacteria and fungi is rare, and to date, there have been no reports of mixed osteomyelitis with Staphylococcus spp. and Microsporum canis. CASE PRESENTATION: This essay reports an atypical presentation of mixed osteomyelitis (Staphylococcus spp...
February 19, 2024: BMC Veterinary Research
https://read.qxmd.com/read/38336355/six-year-experience-with-gm-test-in-hematological-patients-in-a-public-brazilian-tertiary-hospital
#25
JOURNAL ARTICLE
Lucieni Oliveira Conterno, Plínio Trabasso, Mariângela Ribeiro Resende, Paula Sanches Paschoali, Leticia Bergamo Pascucci, Maria Luiza Moretti
UNLABELLED: Invasive fungal infection (IFI) is frequent in patients with hematologic malignancies or submitted hematopoietic stem cell transplantation (HSCT). OBJECTIVES: To evaluate the role of the GM (galactomannan) test in prescribing therapeutic antifungals; to determine invasive aspergillosis (IA) frequency, the factors associated with positive GM test, and the in-hospital mortality. METHODS: We conducted a retrospective observational study including patients aged 18 or over with hematological malignancy or submitted to HSCT...
February 6, 2024: Brazilian Journal of Infectious Diseases
https://read.qxmd.com/read/38335202/mucormycosis-in-children-with-cancer-and-hematopoietic-cell-transplant-a-single-center-cohort-study
#26
JOURNAL ARTICLE
Gabriela A Marón, Kengo Inagaki, Alicia Rodriguez, Katherine M Knapp, Randall T Hayden, Elisabeth E Adderson
Although mucormycosis is an important cause of morbidity and mortality in children with cancer, our understanding of the typical characteristics of these infections is incomplete. We reviewed all cases of mucormycosis diagnosed at a single pediatric cancer center over 5 decades to identify the clinical features of mucormycosis in pediatric oncology patients and to identify risk factors for mortality. There were 44 cases of mucormycosis diagnosed between 1970-2019. Most patients (89%) had hematological malignancies and a history of prolonged and severe neutropenia (91%)...
2024: PloS One
https://read.qxmd.com/read/38331696/prevention-and-management-of-infectious-complications-in-patients-with-chronic-leucocytic-leukemia-cll-treated-with-btk-and-bcl-2-inhibitors-focus-on-current-guidelines
#27
REVIEW
Malgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, Michele Bartoletti, Anna Maria Frustaci, Andrea Visentin, Candida Vitale, Francesca R Mauro
CLL is associated with an increased risk of infectious complications. Treatment with BTK or BCL-2 inhibitors does not seem to increase significantly the risk of opportunistic infections, but the role of combination therapies including BTK and/or BCL-2 inhibitors remains to be established. Various infectious complications can be successfully prevented with appropriate risk management strategies. In this paper we reviewed the international guidelines on prevention and management of infectious complications in patients with CLL treated with BTK or BCL-2 inhibitors...
February 1, 2024: Blood Reviews
https://read.qxmd.com/read/38312215/the-global-and-regional-prevalence-of-hospital-acquired-carbapenem-resistant-klebsiella-pneumoniae-infection-a-systematic-review-and-meta-analysis
#28
REVIEW
Xing-Chen Lin, Chang-Li Li, Shao-Yang Zhang, Xiao-Feng Yang, Meng Jiang
BACKGROUND: Due to scarce therapeutic options, hospital-acquired infections caused by Klebsiella pneumoniae (KP), particularly carbapenem-resistant KP (CRKP), pose enormous threat to patients' health worldwide. This study aimed to characterize the epidemiology and risk factors of CRKP among nosocomial KP infections. METHOD: MEDLINE, Embase, PubMed, and Google Scholar were searched for studies reporting CRKP prevalence from inception to 30 March 2023. Data from eligible publications were extracted and subjected to meta-analysis to obtain global, regional, and country-specific estimates...
February 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38286175/how-do-i-manage-refractory-invasive-pulmonary-aspergillosis
#29
REVIEW
Paschalis Vergidis, Parham Sendi, Hassan B Alkhateeb, M Hong Nguyen
BACKGROUND: Invasive aspergillosis is associated with significant morbidity and mortality in patients with haematologic malignancies and haematopoietic cell transplant recipients. The prognosis is worse among patients who have failed primary antifungal treatment. OBJECTIVES: We aim to provide guidance on the diagnosis and management of refractory invasive pulmonary aspergillosis. SOURCES: Using PubMed, we performed a review of original articles, meta-analyses, and systematic reviews...
January 28, 2024: Clinical Microbiology and Infection
https://read.qxmd.com/read/38270146/multicenter-retrospective-study-of-invasive-fusariosis-in-intensive-care-units-france
#30
REVIEW
Jordane Demonchy, Lucie Biard, Raphaël Clere-Jehl, Florent Wallet, Djamel Mokart, Anne-Sophie Moreau, Laurent Argaud, Camille Verlhac, Frédéric Pène, Alexandre Lautrette, Naïke Bige, Audrey de Jong, Emmanuel Canet, Jean-Pierre Quenot, Nahéma Issa, Yoann Zerbib, Inès Bouard, Muriel Picard, Lara Zafrani
Invasive fusariosis can be life-threatening, especially in immunocompromised patients who require intensive care unit (ICU) admission. We conducted a multicenter retrospective study to describe clinical and biologic characteristics, patient outcomes, and factors associated with death and response to antifungal therapy. We identified 55 patients with invasive fusariosis from 16 ICUs in France during 2002----2020. The mortality rate was high (56%). Fusariosis-related pneumonia occurred in 76% of patients, often leading to acute respiratory failure...
February 2024: Emerging Infectious Diseases
https://read.qxmd.com/read/38257945/high-risk-neutropenic-fever-and-invasive-fungal-diseases-in-patients-with-hematological-malignancies
#31
REVIEW
Giovanni Mori, Sara Diotallevi, Francesca Farina, Riccardo Lolatto, Laura Galli, Matteo Chiurlo, Andrea Acerbis, Elisabetta Xue, Daniela Clerici, Sara Mastaglio, Maria Teresa Lupo Stanghellini, Marco Ripa, Consuelo Corti, Jacopo Peccatori, Massimo Puoti, Massimo Bernardi, Antonella Castagna, Fabio Ciceri, Raffaella Greco, Chiara Oltolini
Invasive fungal diseases (IFDs) still represent a relevant cause of mortality in patients affected by hematological malignancies, especially acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing remission induction chemotherapy, and in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Mold-active antifungal prophylaxis (MAP) has been established as a standard of care. However, breakthrough IFDs (b-IFDs) have emerged as a significant issue, particularly invasive aspergillosis and non- Aspergillus invasive mold diseases...
January 6, 2024: Microorganisms
https://read.qxmd.com/read/38237014/characterization-of-the-use-and-efficacy-of-isavuconazonium-sulfate-in-a-pediatric-oncology-and-stem-cell-transplant-population-a-single-institution-retrospective-review
#32
JOURNAL ARTICLE
Binni Kunvarjee, Molly Siver, Sherry Mathew, Samantha Steiger, Yeon Joo Lee, Barbara Spitzer
Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients receiving ISA for prophylaxis (n=20) or treatment (n=6) of invasive fungal disease (IFD) aims to characterize real-world clinical efficacy and toxicity of ISA in patients <18 years of age. Of 20 patients receiving ISA for prophylaxis, three patients had presumed breakthrough IFD (1 proven, 2 probable/possible)...
January 17, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38227935/cpx-351-exploits-the-gut-microbiota-to-promote-mucosal-barrier-function-colonization-resistance-and-immune-homeostasis
#33
JOURNAL ARTICLE
Giorgia Renga, Emilia Nunzi, Claudia Stincardini, Marilena Pariano, Matteo Puccetti, Giuseppe Pieraccini, Claudia Di Serio, Maurizio Fraziano, Noemi Poerio, Vasileios Oikonomou, Paolo Mosci, Enrico Garaci, Luana Fianchi, Livio Pagano, Luigina Romani
CPX-351, a liposomal combination of cytarabine plus daunorubicin, has been approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes as it improves survival and outcome of haematopoietic stem cell transplanted patients as compared to the continuous infusion of cytarabine plus daunorubicin (referred to as "7+3" combination). Because gut dysbiosis occurring in patients with AML during induction chemotherapy heavily impacts on the subsequent phases of therapy, we have assessed whether the superior activity of CPX-351 versus "7+3" combination in the real-life setting implicates an action on and by the intestinal microbiota...
January 16, 2024: Blood
https://read.qxmd.com/read/38221907/effectiveness-and-safety-of-oral-terbinafine-for-dermatophyte-distal-subungual-onychomycosis
#34
REVIEW
Aditya K Gupta, Shruthi Polla Ravi, Mesbah Talukder, Avantika Mann
INTRODUCTION: Terbinafine has been a cornerstone in dermatophyte infection treatment. Despite its global efficacy, the emergence of terbinafine resistance raises concerns, requiring ongoing vigilance. AREAS COVERED: This paper focuses on evaluating the efficacy and safety of terbinafine in treating dermatophyte toenail infections. Continuous and pulse therapies, with a 24-week continuous regimen and a higher dosage of 500 mg/day have demonstrated superior efficacy to the FDA approved regimen of 250 mg/day x 12 weeks...
January 15, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38156297/cryptococcosis-in-oncology-patients-a-case-series-in-a-tertiary-care-cancer-centre
#35
Sagila Savithri Gangadharan, Swapna Raveendranath
Cryptococcosis, a relatively uncommon infection in cancer patients is often associated with delayed diagnosis and high fatality rate due to its highly heterogeneous and protean manifestations. Early recognition and initiation of appropriate antifungal therapy might have a favourable outcome in such cases. Here we report three cases of Cryptococcosis among cancer patients in a tertiary care cancer centre in South India. All three patients were males of different ages at presentation with immunosuppression in the form of solid organ or hematologic malignancy and were using immunosuppressive medications like steroids or chemotherapeutic agents...
December 2023: Iranian Journal of Microbiology
https://read.qxmd.com/read/38149226/antifungal-effect-of-probiotic-lactobacillus-casei-on-drug-resistant-oral-candida-albicans-isolated-from-patients-with-hematological-malignancy-an-in-vitro-study
#36
JOURNAL ARTICLE
Seyedeh Saba Sharifzadeh, Ensieh Lotfali, Simin Lesan, Taraneh Farrokhnia
STATEMENT OF THE PROBLEM: Candida albicans ( C. albicans ) is recognized as the most common opportunistic pathogen in patients with an impaired immune system, and due to the frequent use of antifungal medicine, a variety of drug-resistant species are developing. Probiotics are a part of the human microbiome and natural competitors of Candida by producing lactic acid, low pH, and other secreted metabolites. The role of probiotics in preventing fungal infections has always been discussed...
December 2023: Journal of Dentistry
https://read.qxmd.com/read/38116484/invasive-fungal-infections-in-hematologic-malignancies-incidence-management-and-antifungal-therapy
#37
REVIEW
Fatemeh Shafiee, Rasool Soltani, Mohsen Meidani
The incidence of invasive fungal infections (IFIs) has increased in recent years as a result of increasing the incidence of hematologic malignancies (HMs). IFIs, as the opportunistic diseases, are the most important concern in these patients with a high mortality rate. These infections are one of the leading causes of morbidity and mortality in HM patients and an important factor in increasing the costs of patients' management because of the prolonged hospitalization and the inevitable need to use antifungal agents...
2023: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://read.qxmd.com/read/38095652/the-evaluation-of-atorvastatin-as-an-adjunct-to-fluconazole-for-the-anti-fungal-prophylaxis-in-acute-myeloid-leukemia-a-multicenter-triple-blinded-randomized-clinical-trial
#38
JOURNAL ARTICLE
Niloufar Saber-Moghaddam, Mohammad Moeini Nodeh, Vahid Ghavami, Hossein Rahimi, Sajjad Ataei Azimi, Mohsen Seddigh-Shamsi, Mostafa Kamandi, Abolghasem Allahyari, Somayeh Sadat Shariatmaghani, Sepideh Elyasi, Omid Arasteh
The development of invasive fungal infections (IFIs) is a serious complication in acute myeloid leukemia (AML) patients who undergo an induction to remission chemotherapy. Given the increased mortality in AML patients with IFI despite prophylaxis, we need to address this problem. Statins have traditionally been employed in clinical settings as agents for reducing lipid levels. Nonetheless, recent investigations have brought to light their antifungal properties in animals, as well as in vitro studies. The objective of this study was to assess the effectiveness of atorvastatin when added to the routine IFI prophylaxis regimen in patients diagnosed with AML...
December 14, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38084692/candidemia-cases-caused-by-candida-parapsilosis-complex-species-epidemiology-and-antifungal-susceptibility-of-strains
#39
JOURNAL ARTICLE
Ozgul Cetinkaya, Ozlem K Ozyurt, Mert A Kuskucu, Betil Ozhak, Gozde Ongut, Hatice Yazisiz, Dilara Ogunc
BACKGROUND: Candida parapsilosis is a common non-albicans Candida species isolated from blood cultures. The increase in fluconazole-resistant C. parapsilosis complex isolates is worrying, especially in strains with Y132F changes in the ERG11 gene since this ultimately leads to outbreaks. This study aimed to investigate the distribution and antifungal susceptibility of C. parapsilosis complex species isolated from bloodstream, clinical characteristics of patients, prevalence of risk factors, and to determine ERG11 gene region mutations in strains that were not susceptible to fluconazole...
December 1, 2023: Clinical Laboratory
https://read.qxmd.com/read/38072427/-severe-neuropsychiatric-disorder-developing-during-busulfan-containing-regimen-for-stem-cell-transplantation
#40
JOURNAL ARTICLE
Naoto Imoto, Shinji Fujiwara, Miki Watanabe, Yutaro Suzuki, Takuya Kawaguchi, Rie Ito, Toshiyasu Sakai, Shingo Kurahashi
Here we describe two patients that required interruption of a busulfan (BU) containing conditioning regimen due to severe mental disorder before stem cell transplantation. The first patient was a 66-year-old man scheduled for unrelated peripheral blood stem cell transplantation with fludarabine/BU conditioning for myelodysplastic syndrome. He received 9.6 mg/kg BU and developed hallucinations that worsened the next day. BU was stopped on the final day, but the patient became comatose (grade 4). He recovered the next day...
2023: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
keyword
keyword
105865
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.